Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in moderate-severe atopic dermatitis
NCT04893941Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Jul 2020; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04893941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893941.